The Claim
Intermittent administration of dasatinib plus quercetin for 20 weeks in postmenopausal women with high baseline T cell p16 mRNA levels increases the bone formation marker P1NP by 34% at 2 weeks, reduces the bone resorption marker CTx by 11% at 2 weeks, and increases radius bone mineral density by 2.7% at 20 weeks.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In postmenopausal women with high levels of a cellular senescence marker, a 20-week course of dasatinib and quercetin increases bone formation by 34%, decreases bone breakdown by 11%, and increases bone density in the radius by 2.7%.
See the scientific wording
Intermittent administration of dasatinib plus quercetin for 20 weeks in postmenopausal women with high baseline T cell p16 mRNA levels increases bone formation marker P1NP by 34% at 2 weeks and reduces bone resorption marker CTx by 11% at 2 weeks, with a 2.7% increase in radius bone mineral density at 20 weeks, suggesting that senolytic therapy may selectively benefit individuals with elevated cellular senescence burden.
Old, damaged cells in bone release a protein that blocks bone building. Removing these cells stops the protein release, allowing bone-forming cells to work faster and bone-breaking cells to slow down, leading to stronger bones over time.
What the research says
1 studyIn women with lots of old, tired cells, a short course of two drugs (dasatinib and quercetin) helped their bones build up faster, break down less, and get slightly denser — but only in those with the most aging cells. In other women, it didn’t work.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.